USA Insider Trading Pulse — August 31, 2026

CEO & Chair Liu Dandan made a massive $3.56M open-market purchase of 2.97M shares at $1.20, increasing her stake by 141%. This is a powerful vote of confidence in a micro-cap, suggesting deep value or a pending catalyst

Three top executives (President, COO, CCO) sold a combined ~$2.5M in shares under 10b5-1 plans. While pre-planned, the coordinated selling by multiple C-suite members at ~$120 is a cautionary signal for the stock's near-term outlook

Exec VP & General Counsel sold $802K worth of stock at $103.32. This large sale by a senior insider, combined with several other executives receiving large option grants, may indicate a strategy to de-risk personal holdings ahead of a volatile period

Vice Chairman sold $1.98M in stock at $151.29, representing a massive 46.5% reduction in his holdings. This is a significant red flag from a top executive at a major industrial company

Director John R. Rakolta Jr. bought $1.47M worth of shares at ~$73.23, a substantial purchase by a director. This signals strong confidence in the REIT's portfolio and dividend sustainability

CFO and a Director made combined open-market purchases of ~$267K at ~$3.20. Insider buying from both the CFO and a board member is a strong signal of internal conviction in the company's turnaround or growth story

CEO and a Director purchased a combined ~$83K in shares at ~$1.50. Insider buying at a biotech, especially by the CEO, is a bullish signal often preceding positive trial data or partnership news

EVP & CFO bought $142K in common stock at $56.64. A CFO buying his own company's stock is a strong signal of financial health and undervaluation in the energy sector

President/Chief Client Officer sold ~$670K in stock at ~$238. While not a massive sale, it is a notable disposition by a key operational executive at a high-multiple software company

EVP & CHRO sold $644K in stock at $196.50. A senior HR executive selling a significant stake can sometimes signal internal concerns about talent retention or company culture

CEO Todd G. Schwartz bought $25K in Class A stock at $7.15. This purchase by the CEO of a fintech lender signals confidence in the company's credit performance and growth trajectory

Chief Accounting Officer sold $178K in stock at $190 under a 10b5-1 plan. While pre-planned, the sale by a key financial officer adds to the pattern of insider profit-taking in high-growth tech

Vice Chairman sold 13,100 shares for $1.98M, reducing his stake by 46.5%. This is a high-conviction sell signal from a top executive at a bellwether industrial company

President, COO, and CCO sold a combined ~$2.5M in shares. The coordination of sales by multiple top executives, even under 10b5-1 plans, creates a negative sentiment overhang

Exec VP & General Counsel sold $802K in stock. This is a large, discretionary-looking sale by a key insider with deep knowledge of legal and regulatory risks

President/Chief Client Officer sold $670K. The sale by the head of client operations could signal headwinds in client acquisition or retention

EVP & CHRO sold $644K in stock. Sales by HR executives are less common and can be a soft indicator of internal morale or retention issues

CEO exercised 11,990 options but sold 2,957 shares immediately. This pattern, while common, suggests the CEO is monetizing options rather than accumulating long-term stock

COO sold $195K in stock at $30.00. A direct open-market sale by an operating executive is a straightforward bearish signal for the cybersecurity firm

Director AULT MILTON C III sold 2,000 shares at $1.56. While small in dollar value, any insider sale in a micro-cap biotech is a notable risk flag

CEO bought $3.56M worth of stock, increasing his stake by 141%. This massive insider purchase in a micro-cap suggests extreme undervaluation or a major upcoming catalyst. A deep-dive is warranted

CFO and a Director bought a combined $267K at ~$3.20. This dual insider buying at a low stock price presents a potential turnaround or value opportunity in the industrial sector

Director bought $1.47M in shares at $73.23. This large purchase in a REIT signals confidence in the real estate portfolio and dividend. It's a strong buy signal for income-focused investors

CEO and Director bought ~$83K at ~$1.50. Insider buying in a pre-revenue biotech is a high-risk, high-reward signal that often precedes positive clinical or regulatory news

EVP & CFO bought $142K at $56.64. A CFO purchase is a strong signal of financial health. This could be an opportunity in the energy sector if oil prices remain supportive

CEO bought $25K in stock at $7.15. This purchase by the CEO of a fintech lender is a bullish signal on the company's credit cycle and growth prospects, potentially marking a bottom

Director bought $105K in stock at $5.23. This purchase by a director at a beaten-down media measurement company could signal a turnaround or value play

Four directors were each awarded 71,770 RSUs. While not a purchase, these large equity grants align board interests with shareholders and can be a precursor to positive strategic moves

The data shows a clear divide. Executives at large-cap tech (Sea Ltd, Atlassian, Paycom) are selling shares, often under 10b5-1 plans. In contrast, insiders at small/micro-caps (TDH Holdings, SCHMID, Veraxa) are aggressively buying. This suggests a rotation of insider capital from crowded, high-valuation tech into overlooked value plays.

The financial sector shows a notable cluster of insider buying. Agree Realty (REIT), Matador Resources (Energy/Financial), and First Guaranty Bancshares (Bank) all saw insider purchases. This contrasts with the broader market and suggests insiders see value in yield-oriented and asset-heavy sectors.

Insider activity in biotech is extreme. Veraxa Biotech saw bullish buying from CEO and Director, while Alzamend Neuro saw a director sale. This binary nature highlights the event-driven risk/reward profile of the sector, where insider moves can be highly predictive of upcoming catalysts.

A significant portion of insider selling (Sea Ltd, Atlassian, Figma) was executed under Rule 10b5-1 plans. While these plans provide a legal defense, the sheer volume of sales from multiple executives at the same companies creates a bearish undertone that investors should not ignore.

Corning Inc saw a massive sale from its Vice Chairman, a bearish signal. Conversely, SCHMID Group saw strong buying from its CFO and a Director. This divergence suggests that within the industrial sector, specific company fundamentals are driving insider behavior more than a sector-wide trend.

Watch for any additional Form 4 filings from other Sea Ltd executives. The coordinated selling by the President, COO, and CCO warrants close monitoring for the company's next earnings call and any changes to its growth outlook.

The large option grants to several EVPs (Canevari, Hertzmark Hudis, Webster, Shrivastava) suggest a new long-term incentive plan. Monitor for details on performance targets, as these could signal management's internal goals for the stock price.

With the Vice Chairman selling 46.5% of his holdings, monitor for any further sales. If he continues to sell, it would be a strong negative signal for the stock.

The CEO's massive $3.56M purchase is a major event. Watch for any company announcements, such as a new business line, a large contract, or a strategic shift that could explain the CEO's conviction.

The large RSU grants to four directors vest over time. Monitor for any director purchases on the open market as the RSUs vest, which would be an even stronger bullish signal.

Director Rakolta's $1.47M purchase is a strong signal. Watch for any additional buying by him or other directors, which would confirm the bullish thesis on the REIT.

The insider buying by the CEO and Director strongly suggests an upcoming catalyst. Monitor for news on clinical trial results, partnerships, or financing rounds.

After the President/Chief Client Officer sold $670K, monitor for any further sales. A pattern of selling by this key executive would be a significant red flag for the company's growth trajectory.